News Archive

SomaScan® Platform Reveals Space Mice Story

On December 5, 40 special mice were launched inside a Dragon capsule on a new Falcon 9 booster rocket from Cape Canaveral Air Force Station, headed toward the International Space Station for a 33-day mission. The SomaScan® Assay was used to measure proteomic changes in the mice after their spaceflight and revealed certain biochemical pathways that can be blocked to protect against both muscle and bone loss.

read more

SomaLogic Announces New Agreement with Amgen to Accelerate Drug Discovery and Development Efforts through Comprehensive Proteomic Profiling

SomaLogic, Inc. announced today an agreement with Amgen that will use SomaLogic’s proprietary proteomics technology to help advance Amgen’s drug discovery and development programs. The agreement builds upon SomaLogic’s existing collaboration with deCODE genetics, an Amgen subsidiary based in Iceland, and will include broader application across Amgen’s pipeline.

read more

Somalogic and NEC Solution Innovators Announce Launch of Foneslife Corporation

SomaLogic, Inc. and NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, announced today the establishment of FonesLife Corporation, a new Tokyo-based company that will bring a series of new clinical health management tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese people.

read more

Statement on SomaLogic’s commitment to diversity by Roy Smythe, CEO

At SomaLogic, we measure proteins in the human body, and derive important health insights from that information for each individual. Depending on the day, the expression of these proteins in each individual human body can vary significantly, and we analyze this variability to discern patterns that may predict current conditions or future disease. But however variable the expression may be, we also know that the identity of every individual’s proteins are the same, regardless of skin color, country of origin, gender, religious preference or socioeconomic status. We always measure these proteins the same way because we know there is only one species of human beings.

read more

SomaLogic announces new phase of partnership with NEC Solution Innovators

Today SomaLogic, Inc. announced an enhanced collaboration with NEC Solution Innovators, Ltd. of Japan, a subsidiary of NEC Corporation, that builds on the companies’ ten-year partnership by bringing new clinical tests based on SomaLogic’s proprietary protein-measurement technology to the Japanese population.

read more

SomaScan proteomic technology is now broadly available to COVID-19 researchers and drug developers to expand and accelerate response to the pandemic

SomaLogic today launched a new initiative to deploy their proteomic technology against the coronavirus pandemic. The company is making its proprietary SomaScan® Assay available to biopharma companies, academic medical investigators, and government entities working on COVID-19/SARS-CoV-2 infection under simplified terms, with data from non-pharma studies to be shared rapidly and widely.

read more

Blood test beats traditional predictors of multiple disease risks

Proteins in our blood could in future help provide a comprehensive way to assess our health status and predict the likelihood that we will develop a range of diseases, according to research published today in Nature Medicine. The study, by an international team of researchers led by scientists at the University of California, San Francisco, Cambridge University in the UK and SomaLogic, shows that large-scale measurement of proteins in a single blood test can provide important information about a wide range of health factors and can help to predict a range of disease risks.

read more